Using flow cytometry, we confirmed that ASO FOXP3 treatment resulted in decreased numbers of all cancer Tregs (Figures 2G–I, Supplementary Figures 2A, B) including intratumoral Tregs, analyzed separately (Supplementary Figures 2A, B). This evidence concerns the gene FOXP3 and cancer.